semaglutide alzheimer clinical trial Novo Nordisk said Monday that an older oral version of its diabetes treatment, semaglutide, failed to meet its main goal in late-stage trials assessing whether it could slow cognitive decline in Alzheimer's evoke and evoke+: design of

reported that never-smoking patients with chronic beryllium disease (CBD) displayed higher extracellular GPX activity in BALF than ex-smoking CBD patients 49

BPC-157, used rigorously and within the limits of current evidence, is one of the more interesting tools available for addressing that decline at a mechanistic level

China GLP-1 Receptor Agonist Market Analysis The China GLP-1 receptor agonist market was valued at USD 2.35 billion in 2025, supported by rapid emergence of domestic peptide drug developers, increasing government support for innovative biologics under national healthcare reforms, and expanding local manufacturing capacity for metabolic therapies

[DOI] [PMC free article] [PubMed] [Google Scholar] 34